Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Breast cancer
Low-dose RT (9Gy) + pembrolizumab boosts early T-cell infiltration and trends to higher nodal clearance in node+ TNBC
TBCRC-053 (P-RAD; NCT04443348) tested adding preoperative breast-only radiation (0Gy vs 9Gy vs 24Gy) concurrently with pembrolizumab to a KEYNOTE-522–like neoadjuvant backbone (paclitaxel/carboplatin → AC, all with…
NCT04443348 - Trial result
Breast cancer
RT→pembrolizumab (PD-1) preop window yields higher major pathologic response than pembrolizumab→RT in early breast cancer
Pembrolizumab is an anti–PD-1 immune checkpoint inhibitor, and this Phase 1b/2 multi-arm adaptive “window-of-opportunity” study (NCT04454528) tested whether a single 7Gy RT fraction sequenced before vs after a single…
NCT04454528 - Trial result
Breast cancer
Sacituzumab govitecan (TROP2 ADC delivering SN-38) extends PFS vs taxane or gem/carbo across Trop-2, tBRCA, and HER2-low subgroups in 1L advanced TNBC
Sacituzumab govitecan (SG) is a TROP2-targeted antibody–drug conjugate delivering the topo-I inhibitor payload SN-38; in the Phase 3 ASCENT-03 trial (NCT05382299), previously untreated locally advanced…
NCT05382299 - Trial result
Breast cancer
Vepdegestrant (PROTAC ER degrader) + abemaciclib delivers 30.6% ORR (45.0% in ESR1m) post-CDK4/6 in ER+/HER2− ABC
Vepdegestrant is an oral proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader combined with abemaciclib, an oral CDK4/6 inhibitor, in Substudy A of the open-label Phase 1b/2 TACTIVE-U umbrella study…
NCT05548127 - Trial result
Breast cancer
Elacestrant (oral SERD) + capivasertib (AKT inhibitor) posts 11.3-mo mPFS in post-CDK4/6 ER+/HER2− ABC (Ph 1b)
Elacestrant is an oral selective estrogen receptor degrader (SERD) combined here with capivasertib, an oral AKT inhibitor, to address endocrine resistance driven by ESR1 mutations and PI3K/AKT/PTEN pathway…
NCT05563220 - Trial result
Breast cancer
Tersolisib (LY4064809/STX-478) mutant-selective PI3Kα inhibitor shows 19–35% ORR with low hyperglycemia in PIK3CA-mutant HR+/HER2- ABC
Tersolisib is an oral, allosteric, CNS-penetrant, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type PI3Kα and potentially reduce PI3K-inhibitor class toxicities; in the PIKALO-1 Phase 1/2 trial…
NCT05768139 - Trial result
Breast cancer
Sacituzumab govitecan (TROP2 ADC) trends toward longer PFS vs chemo in HER2 IHC0 HR+/HER2− mBC (ASCENT-07 subgroup)
Sacituzumab govitecan (SG; a TROP2-directed antibody–drug conjugate delivering SN-38) was compared with chemotherapy treatment of physician’s choice (TPC: capecitabine, paclitaxel, or nab-paclitaxel) in the Phase 3…
NCT05840211 - Trial result
Breast cancer
Zeta-BC-003 (p21-pathway intratumoral biomaterial) drives CT/MRI lytic defect shrinkage and 0 SREs in MBC bone mets
Zeta-BC-003 is a first-in-class intratumoral injectable biomaterial infused with N-allyl noroxymorphone, designed to activate the p21 pathway to promote bone healing alongside local tumor control. In the open-label…
NCT05280067 - Trial result
Breast cancer
BGB-43395 (selective CDK4 inhibitor) + letrozole shows high early ORR with low neutropenia in 1L HR+/HER2− mBC
BGB-43395 is an oral, highly selective CDK4 inhibitor (designed to spare CDK6) combined with the aromatase inhibitor letrozole in an open-label Phase 1a/1b safety-expansion (cohort 2) for CDK4/6i-naive…
NCT06120283 - Trial result
Breast cancer
Vepdegestrant (PROTAC ER degrader) + atirmociclib (selective CDK4 inhibitor) delivers 9–12mo mPFS post-CDK4/6i in ER+/HER2− ABC
Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) designed to degrade estrogen receptor, combined here with atirmociclib (ATI; a selective CDK4 inhibitor) in the open-label, multicenter TACTIVE-K Phase…
NCT06206837 - Trial result
Breast cancer
Atirmociclib (selective CDK4 inhibitor) + letrozole drives 88% Ki-67 CCCA at Day 14 in HR+/HER2− early breast cancer
Atirmociclib (PF-07220060) is an oral, CDK4-selective inhibitor designed to deepen cell-cycle arrest with potentially less dose-limiting toxicity than less-selective CDK4/6 inhibition; in the randomized Phase 2…
NCT06465368 - Trial result
Breast cancer
PLD + Pembrolizumab (Anthracycline/PD-1) Delivers 33% ORR in ER+ MBC
PEG-liposomal doxorubicin (PLD), an anthracycline formulation that may induce immunogenic cell death, was combined with pembrolizumab PD-1 blockade in a Phase 1b trial of ER+/HER2− metastatic breast cancer after…
NCT03591276 - Trial result
Breast cancer
Giredestrant (oral SERD; ER degrader) + palbociclib misses 1L PFS significance vs letrozole + palbociclib in ER+/HER2– mBC
Giredestrant (GIRE) is a next-generation oral selective estrogen receptor antagonist/degrader (SERD) evaluated in the phase III, double-blind persevERA BC trial (NCT04546009) as first-line therapy with palbociclib…
NCT04546009 - Trial result
Breast cancer
Camizestrant (oral SERD/complete ER antagonist) switch at emergent ESR1m extends PFS2 in 1L HR+/HER2− ABC (SERENA-6)
Camizestrant (CAMI) is a next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist tested in the Phase III, ctDNA-guided SERENA-6 switch strategy (NCT04964934): pts with HR+/HER2−…
NCT04964934 - Trial result
Breast cancer
Tucatinib + trastuzumab/pertuzumab extends HER2+ mBC maintenance PFS, but adds liver AEs
Tucatinib is an oral HER2-selective TKI added to trastuzumab + pertuzumab maintenance after taxane + HP induction in HER2-positive metastatic breast cancer, testing whether HER2 blockade can be intensified after…
NCT05132582 - Trial result
Breast cancer
Sacituzumab govitecan (TROP2-directed ADC delivering SN-38) extends PFS2 to 18.2mo vs chemo in 1L PD-(L)1–ineligible mTNBC
Sacituzumab govitecan (SG) is a TROP2-targeted antibody–drug conjugate that delivers the topoisomerase I inhibitor payload SN-38; in the Phase 3 ASCENT-03 trial (NCT05382299), previously untreated metastatic TNBC…
NCT05382299 - Trial result
Breast cancer
Giredestrant (oral SERD/full ER antagonist) + everolimus extends PFS2 and chemo-free survival post-CDK4/6 in ER+ aBC
Giredestrant (GIRE) is an oral selective estrogen receptor degrader (SERD) and full ER antagonist combined with everolimus (E; mTOR inhibitor) in the Phase III evERA Breast Cancer trial (NCT05306340) in ER+, HER2–…
NCT05306340 - New trial
Breast cancer
Phase 2 trastuzumab deruxtecan (HER2 ADC; topoisomerase I payload) + lovastatin (HMG‑CoA inhibitor)
Washington University School of Medicine is running this Phase 2 study testing whether short “priming” with lovastatin—an HMG‑CoA reductase inhibitor used for cholesterol lowering—can modulate membrane biology (via…
NCT07619365 Exploratory - New trial
Breast cancer
Phase 3 RxFINE-Low: ribociclib CDK4/6 inhibitor guided by Oncotype DX genomic risk
This National Cancer Institute–sponsored, randomized Phase 3 trial tests whether patients with high anatomic-stage ER-positive/HER2-negative breast cancer but low genomic recurrence risk (Oncotype DX Recurrence Score…
NCT07391774 Exploratory - New trial
Breast cancer
Phase 1/1b IEV407 trial tests an undisclosed-target agent with endocrine therapy in HR+/HER2- breast cancer.
No disclosed MOA. We do not include details of trials without this basic information.
NCT07604571 First-in-human - New trial
Brain and CNS tumors
Phase 1b vorasidenib (dual mutant IDH1/IDH2 inhibitor) plus lomustine alkylator in recurrent IDH-mutant glioma
This Phase 1b, open-label, dose-escalation study (VALIENT) is designed to test whether vorasidenib—a brain-penetrant small-molecule mutant IDH1/IDH2 inhibitor marketed as Voranigo by Servier—can be combined safely…
NCT07629089 Exploratory - New trial
Brain and CNS tumors
Phase 2 cemiplimab PD-1 inhibitor + LITT ablation vs chemo after LITT in rGBM
This randomized Phase 2 study tests whether adding cemiplimab (Regeneron/Sanofi; a PD‑1/CD279–blocking monoclonal antibody that reactivates antitumor T cells) after laser interstitial thermal therapy (LITT;…
NCT07620548 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 3 calderasib (MK-1084) KRAS G12C inhibitor + durvalumab PD-L1 antibody after CCRT
Merck Sharp & Dohme (Merck/MSD) is running KANDLELIT-015 (MK-1084-015), a Phase 3 randomized, triple-blind, parallel-group trial in unresected stage II (node-positive) to stage III, predominantly nonsquamous NSCLC…
NCT07554339 Registrational - New trial
Non-small cell lung cancer
Phase 1 64Cu-DOTA-pembrolizumab PET radiotracer targets PD-1 to guide SBRT decisions
City of Hope is running this Phase 1 pilot to test safety, feasibility, and imaging performance of 64Cu‑DOTA‑pembrolizumab (64CDP)—a PET radiotracer made by chelating copper‑64 to pembrolizumab (Merck/MSD’s…
NCT07619599 Exploratory - New trial
Non-small cell lung cancer
Phase 1 tepotinib + ivonescimab trial tests MET inhibitor plus PD-1×VEGF bispecific.
Memorial Sloan Kettering Cancer Center is running this Phase 1 pilot to establish a tolerable and preliminarily active combination of tepotinib (a small-molecule MET/c-Met/HGFR tyrosine kinase inhibitor; Merck…
NCT07619339 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1b pivekimab sunirine CD123-targeted antibody–drug conjugate in pediatric R/R AML
AbbVie is running this open-label, single-arm Phase 1b study to characterize safety, tolerability, and pharmacokinetics of pivekimab sunirine in children with relapsed or refractory acute myeloid leukemia whose…
NCT07306832 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 2 venetoclax (BCL-2 inhibitor) vs gemtuzumab ozogamicin (CD33 ADC) with 7+3 in CBF-AML
This National Cancer Institute (NCI) MyeloMATCH Phase 2, randomized treatment substudy tests whether adding AbbVie/Genentech’s venetoclax (a small-molecule BCL-2 inhibitor that promotes apoptosis) to standard “7+3”…
NCT06917911 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1 ATRN-119 ATR kinase inhibitor plus decitabine (DNA methyltransferase inhibitor) in TP53 AML/MDS.
This single-center, open-label Phase 1 study at Washington University School of Medicine (St. Louis) evaluates ATRN-119 (Aprea Therapeutics; an oral small-molecule inhibitor of ATR, a key DNA damage–response kinase)…
NCT07617363 Exploratory - New trial
Brain and CNS tumors
Phase 2 zanzalintinib c-MET/HGFR and VEGFR inhibitor for recurrent/progressive meningioma
This Phase 2, single-arm, multicenter, open-label study evaluates zanzalintinib (Exelixis)—an oral small-molecule tyrosine kinase inhibitor of c-MET/HGFR and VEGFR—aiming to suppress tumor growth signaling and…
NCT07428616 Exploratory - New trial
Melanoma
Phase 1 Circadian-Optimized Light Therapy (COLT) supports TIL cell therapy via circadian entrainment.
This single-center, prospective Phase 1 pilot from City of Hope tests whether Circadian-Optimized Light Therapy (COLT)—a timed morning light-exposure program delivered through the Circadian OS iPad app—can be safely…
NCT07628894 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.